| Health systems are facing pressures to | Because |
|---|---|
| Expand early detection efforts at scale | Approximately 2 million new cancer diagnoses expected in 2026 |
| Improve outcomes and reduce cost of care through screening | Earlier diagnosis has contributed to increased survival for some cancers by increasing the likelihood of treatment success |
| Provide high-quality care despite staffing and capacity constraints | Innovative, noninvasive, low-cost solutions may help increase cancer screening uptake |
| Meet population health, equity, and quality goals | Increasing access to cancer screenings may help address health disparities |
Cancer screening solutions
Exceptional cancer care starts with early detection
Loading component...
It's time to consider a collaborator who can deliver more toward your cancer screening program.
Real-world experience
See how other health systems have successfully collaborated with Exact Sciences to improve cancer screening.
Navigating the challenges of colorectal cancer screening
The rising incidence of colorectal cancer (CRC) in people younger than 55 years prompted the USPSTF and other organizations to lower the recommended screening age from 50 to 45 years.4,5 Yet CRC screening using colonoscopy alone cannot close the screening gap.6 Is your health system prepared to meet this challenge?
The Cologuard Plus® test
Screening with the Cologuard® test can help your system achieve quality and population health goals, while supporting key priorities and initiatives:
- Adhere to clinical guidelines and improve quality measure performance
4,5,7 - Enhance patient experience
8 and screening completion rates9 - Ensure access and affordability
7
Multi-cancer early detection (MCED)
The Cancerguard® test complements standard-of-care screening and can help detect multiple cancers with a simple blood draw.
- Designed to help detect 50+ cancer types and subtypes by using multiple biomarker classes
10,11 - Demonstrates high specificity (97.4%), helping minimize false positives and reduce unnecessary diagnostic testing
10,* - Expands early detection opportunities, even for aggressive cancers such as pancreatic, liver, lung, and ovarian
10
Connect with us
Let’s discuss how we can support your health system’s cancer screening goals.
Footnotes and references
Important Information about the Cologuard products
Indications for Use
The Cologuard® and Cologuard Plus® tests are intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. A positive result may indicate the presence of colorectal cancer (CRC) or advanced precancerous lesions (APL) and should be followed by a colonoscopy. The Cologuard test and Cologuard Plus test are indicated to screen adults of either sex, 45 years or older, who are at average risk for CRC. These tests are not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.
Contraindications
The Cologuard products are not for high-risk individuals, including patients who have the following:
- a personal history of colorectal cancer or precancerous colon polyps
- a positive result from another colorectal cancer screening method within that test's recommended screening interval
- have been diagnosed with a condition associated with high risk for colorectal cancer such as inflammatory bowel disease (IBD), chronic ulcerative colitis (UC), Crohn’s disease
- have a first-degree family history of colorectal cancer, or certain hereditary syndromes
Patients should talk to a healthcare provider if any of these situations apply.
Warnings and Precautions
All positive results should be referred to colonoscopy.
The Cologuard products may produce false positive and false negative results. A false positive result occurs when a result is positive, even though a colonoscopy will not find CRC or APL. A false negative result occurs when a result is negative, even when a colonoscopy identifies APL or CRC.
A negative result does not guarantee the absence of colorectal cancer or advanced adenoma. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Performance when used for repeat testing has not been established.
Refer to the Cologuard test Clinician Brochure or the Cologuard Plus test Clinician Brochure for additional information about the benefits and risks of using each version of the Cologuard product for CRC screening.
Rx only.